Spots Global Cancer Trial Database for lymphomas
Every month we try and update this database with for lymphomas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas | NCT00389077 | Tumors Lymphomas | Perifosine | 18 Years - | AEterna Zentaris | |
| This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas | NCT02171260 | Pediatrics Solid Tumors | Eribulin Mesyla... | 6 Months - 17 Years | Eisai Inc. | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval | NCT01525394 | Refractory Soli... Lymphomas | Lenvatinib Moxifloxacin 40... Placebos (match... | 18 Years - | Eisai Inc. | |
| Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma | NCT00322608 | Cancer | NPI-2358 | 18 Years - | Nereus Pharmaceuticals, Inc. | |
| Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor | NCT01212341 | Malignant Lymph... Solid Tumors | Allogeneic NK c... | 18 Years - | Seoul National University Hospital | |
| Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies | NCT01065025 | Advanced and In... Malignant Lymph... | 4SC-205 | 18 Years - | 4SC AG | |
| Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | NCT00947739 | Advanced Solid ... Lymphomas | Camptothecin-20... | 18 Years - | New Mexico Cancer Care Alliance | |
| Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor | NCT01212341 | Malignant Lymph... Solid Tumors | Allogeneic NK c... | 18 Years - | Seoul National University Hospital | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation | NCT01203020 | Hodgkin's Lymph... Non-Hodgkin's L... | Busulfan Fludarabine | 18 Years - 70 Years | West Virginia University | |
| Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies | NCT00629473 | Advanced Cancer | NPI-0052 on Day... NPI-0052 on Day... Dexamethasone | 18 Years - | Celgene | |
| Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | NCT00222443 | Lymphomas Tumors | Irinotecan | 1 Year - 21 Years | University of Oklahoma | |
| Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology | NCT02140736 | Chemotherapy-in... Solid Tumors Malignant Hemop... Lymphomas Myelomas | Epoetin biosimi... | 18 Years - | Hospira, now a wholly owned subsidiary of Pfizer | |
| Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology | NCT02140736 | Chemotherapy-in... Solid Tumors Malignant Hemop... Lymphomas Myelomas | Epoetin biosimi... | 18 Years - | Hospira, now a wholly owned subsidiary of Pfizer | |
| Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | NCT00947739 | Advanced Solid ... Lymphomas | Camptothecin-20... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. | NCT01237236 | Advanced Solid ... Lymphomas | LEE011 | 18 Years - | Novartis | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | NCT05773040 | Lymphomas B-cell Lymphoma... | JV-213 Leukapheresis | 18 Years - | M.D. Anderson Cancer Center | |
| tTF-NGR Phase I Study | NCT02902237 | Malignant Solid... Lymphomas | tTF-NGR | 18 Years - | University Hospital Muenster | |
| A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | NCT02096341 | Malignant Solid... Lymphomas | RRx-001 | 18 Years - | EpicentRx, Inc. | |
| Assess the Oral Bioavailability of New ABT-263 Formulations | NCT00743028 | Chronic Lymphoc... Lymphomas Leukemias | ABT-263 ABT-263 ABT-263 | 18 Years - | Abbott | |
| Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas | NCT03985696 | Lymphoma, B-cel... | blood sample | 18 Years - | University Hospital, Limoges | |
| R Retreatment in 1st Relapsed DLBCL | NCT00980304 | Lymphomas | Rituximab | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma | NCT00322608 | Cancer | NPI-2358 | 18 Years - | Nereus Pharmaceuticals, Inc. | |
| Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. | NCT02452099 | Multiple Myelom... Lymphomas Leukemias | Cryopreservatio... Cryopreservatio... Cryopreservatio... | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | NCT02661542 | Solid Tumors Lymphomas | FF-10502-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | NCT00947739 | Advanced Solid ... Lymphomas | Camptothecin-20... | 18 Years - | New Mexico Cancer Care Alliance | |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | NCT02786485 | Leukemia Myelodysplastic... Lymphomas Multiple Myelom... Other High-risk... | rivogenlecleuce... Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | NCT01512758 | Advanced Solid ... Lymphomas | Alisertib | 18 Years - | Takeda | |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | NCT03188965 | Advanced Solid ... Non-Hodgkin's L... Mantle Cell Lym... | Elimusertib (BA... | 18 Years - | Bayer | |
| Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas | NCT01828008 | Lymphomas | 18 Years - 90 Years | Chinese PLA General Hospital | ||
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | NCT01512758 | Advanced Solid ... Lymphomas | Alisertib | 18 Years - | Takeda | |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | NCT03934372 | Acute Myeloid L... Accelerated Pha... Blast Phase Chr... Chronic Phase C... Acute Lymphobla... Acute Lymphocyt... Leukemia Lymphoma Solid Tumors | Ponatinib | 1 Year - 17 Years | Incyte Corporation | |
| An Open Label Dose Escalation Study Of E7080 | NCT00121719 | Solid Tumor or ... | Lenvatinib | 18 Years - | Eisai Inc. | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas | NCT00152126 | Neuroblastoma Central Nervous... Lymphomas Wilms Tumor | Stem Cell Trans... Busulfan, Melph... | - 25 Years | St. Jude Children's Research Hospital | |
| Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | NCT02661542 | Solid Tumors Lymphomas | FF-10502-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. | NCT01237236 | Advanced Solid ... Lymphomas | LEE011 | 18 Years - | Novartis | |
| Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | NCT00222443 | Lymphomas Tumors | Irinotecan | 1 Year - 21 Years | University of Oklahoma | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas | NCT03985696 | Lymphoma, B-cel... | blood sample | 18 Years - | University Hospital, Limoges | |
| Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques | NCT04417803 | Lymphomas | Blood sampling | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| Collection of Tissue Samples for Cancer Research | NCT00900198 | Neoplasms Lymphomas Multiple Myelom... Myelodysplastic... | Biopsy | 2 Months - | National Institutes of Health Clinical Center (CC) | |
| A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | NCT02048488 | Solid Tumors Lymphomas | TSR-011 | 18 Years - | Tesaro, Inc. | |
| Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas | NCT00788099 | Advanced Solid ... Lymphomas | Plitidepsin and... Gemcitabine and... | 18 Years - | PharmaMar | |
| Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | NCT01490047 | Solid Tumors Lymphomas | Recombinant hum... Liposomal doxor... Caelyx Recombinant hum... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | NCT05773040 | Lymphomas B-cell Lymphoma... | JV-213 Leukapheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | NCT00592163 | Advanced Solid ... Lymphomas | ZIO-101-C (Dari... | 18 Years - | Alaunos Therapeutics | |
| A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | NCT04464798 | Lymphoma | CC-220 Rituximab Obinutuzumab | 18 Years - | Celgene | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours | NCT01194193 | Cancer Advanced Solid ... Lymphomas | AZD8055 | 18 Years - | AstraZeneca | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas | NCT00788099 | Advanced Solid ... Lymphomas | Plitidepsin and... Gemcitabine and... | 18 Years - | PharmaMar | |
| A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | NCT03128164 | Lymphomas | HMPL-689 | 18 Years - | Hutchmed | |
| Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques | NCT04417803 | Lymphomas | Blood sampling | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects | NCT01359982 | Malignant Solid... Lymphomas | RRx-001 RRx-001 RRx-001 RRx-001 RRx-001 RRx-001 | 18 Years - | EpicentRx, Inc. | |
| R Retreatment in 1st Relapsed DLBCL | NCT00980304 | Lymphomas | Rituximab | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma | NCT00322608 | Cancer | NPI-2358 | 18 Years - | Nereus Pharmaceuticals, Inc. | |
| Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | NCT00796562 | MDS Leukemias Lymphomas | Busulfan Cyclophosphamid... Total body irra... | 6 Months - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting | NCT01387841 | Breast Cancer Malignant Femal... Lymphomas Chemotherapy-in... | yoga Jacobsons PMRT ... | 30 Years - 70 Years | Bharath Charitable Cancer Hospital and Institute | |
| A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | NCT04464798 | Lymphoma | CC-220 Rituximab Obinutuzumab | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
